Regenerative Medical Technology Group Inc. (RMTG)
Regenerative Medical Technology Group Inc. (RMTG)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,061,448 | 956,718 | 1,185,695 | 1,614,254 |
| Accounts receivable | 34,821 | 43,815 | 114,006 | 36,676 |
| Inventory | 298,201 | 159,277 | 155,886 | 105,688 |
| Prepaid expenses | 171,253 | 62,950 | 54,864 | 154,864 |
| Total current assets | 1,565,724 | 1,222,760 | 1,510,451 | 1,911,482 |
| Property and equipment, net | 1,112,844 | 870,759 | 677,544 | 504,409 |
| Other assets | 32,538 | 32,538 | 27,264 | 7,264 |
| Intangible assets | 487,700 | 487,700 | 487,700 | NaN |
| Less accumulated amortization | 450,621 | 426,236 | 401,851 | NaN |
| Intangible assets, net | 37,079 | 61,464 | 85,849 | 110,234 |
| Right of use asset, net | 581,419 | 621,195 | 538,741 | 273,461 |
| Goodwill | 1,679,978 | 1,679,978 | 1,679,978 | 1,679,978 |
| Total assets | 5,009,582 | 4,488,694 | 4,519,827 | 4,486,828 |
| Accounts payable and accrued liabilities | 205,152 | 348,394 | 337,595 | 179,538 |
| Accrued interest | 18,019,929 | 16,559,277 | 15,368,806 | 12,396,257 |
| Customer advances | 504,892 | 351,193 | 172,146 | 121,770 |
| Derivative liability | 1,322,060 | 2,406,552 | 7,029 | 6,166 |
| Lease liability, current portion | 165,567 | 219,973 | 186,516 | 64,176 |
| Convertible notes payable, net | 47,452 | 47,452 | 43,138 | 43,138 |
| Notes payable-related parties | 7,800 | 7,800 | 7,800 | 7,800 |
| Notes payable, net | 17,931,876 | 16,883,979 | 1,150,135 | 17,722,932 |
| Total current liabilities | 38,204,727 | 36,824,620 | 17,273,165 | 30,541,777 |
| Lease liability, net of current portion | 426,165 | 409,110 | 357,272 | 209,285 |
| Notes payable, net of current portion | 1,999,999 | 1,999,999 | 16,943,831 | 2,757,016 |
| Total liabilities | 40,630,891 | 39,233,729 | 34,574,268 | 33,508,078 |
| Preferred stock, value-Series APreferred Stock | 1,050 | 1,050 | 1,050 | 1,050 |
| Preferred stock, value-Series CPreferred Stock | 1 | 1 | 1 | 1 |
| Preferred stock, value-Series DPreferred Stock | 10 | 10 | 10 | 10 |
| Common stock, 0.001 par value 100,000,000 shares authorized 13,138,968 issued and outstanding as of march 31, 2026, and december 31, 2025, respectively | 13,139 | 13,139 | 12,539 | 12,539 |
| Additional paid in capital | 40,606,276 | 40,606,276 | 43,904,627 | 40,584,077 |
| Accumulated deficit | -76,241,785 | -75,365,511 | -73,972,668 | -69,618,927 |
| Total stockholders deficit | -35,621,309 | -34,745,035 | -30,054,441 | -29,021,250 |
| Total liabilities and stockholders deficit | 5,009,582 | 4,488,694 | 4,519,827 | 4,486,828 |